A Phase 1 interventional study of Tamsulosin hydrochloride, very low dose and Tamsulosin hydrochloride, low dose in Urination Disorders, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 5 Years to 15 Years. Per ClinicalTrials.gov, last updated 2014-10-17.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To investigate pharmacokinetics, safety, and tolerability of tamsulosin hydrochloride in children with voiding disorders
25 studies on the registry are indexed under Urination Disorders; 5 are open to participants now.
This study's enrollment of 48 is below the median of 113 across 19 interventional studies indexed under Urination Disorders.
Browse Urination Disorders studies →Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Tamsulosin hydrochloride, very low dose
Drug: Tamsulosin hydrochloride, low dose
Drug: Tamsulosin hydrochloride, medium dose
Drug: Tamsulosin hydrochloride, high dose
Also known as: Flomax®
Also known as: Flomax®
Also known as: Flomax®
Also known as: Flomax®
Maximum concentration of the analyte in plasma (Cmax)
Time frame: Up to 26 hours after drug administration
Time from dosing to maximum concentration of the analyte in plasma (tmax)
Time frame: Up to 26 hours after drug administration
Area under the concentration-time curve of the analyte in plasma (AUC)
Time frame: Up to 26 hours after drug administration
Percentage of the AUC0-∞ that is obtained by extrapolation (%AUCtz-∞)
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity after single-dose administration (AUC0-∞)
Time frame: Up to 26 hours after drug administration
Terminal rate constant of the analyte in plasma (λz)
Time frame: Up to 26 hours after drug administration
Terminal half-life of the analyte in plasma (t1/2)
Time frame: Up to 26 hours after drug administration
Mean residence time of the analyte in the body after po administration (MRTpo)
Time frame: Up to 26 hours after drug administration
Apparent clearance of the analyte in the plasma after extravascular administration (CL/F)
Time frame: Up to 26 hours after drug administration
Apparent volume of distribution during the terminal phase λz following an extravascular dose (Vz/F)
Time frame: Up to 26 hours after drug administration
Weight-normalized Cmax
Time frame: Up to 26 hours after drug administration
Weight-normalized AUC0-∞
Time frame: Up to 26 hours after drug administration
Weight-normalized (AUC0-tz)
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable drug plasma concentration after single-dose administration (AUC0-tz)
Time frame: Up to 26 hours after drug administration
Number of patients with clinically relevant changes in physical examination
Time frame: Pre-dose, up to 26 hours after drug administration
Number of patients with clinically relevant changes in vital signs (blood pressure, pulse rate, respiratory rate)
Time frame: Pre-dose, up to 26 hours after drug administration
Number of patients with clinically relevant changes from baseline in orthostatic test
Time frame: Pre-dose and 4 hours after drug administration
Number of patients with clinically relevant changes in 12-lead ECG
Time frame: Pre-dose, up to 26 hours after drug administration
Number of patients with clinically relevant changes from baseline in laboratory tests
Time frame: Pre-dose and 26 hours after drug administration
Number of patients with adverse events
Time frame: Up to 7 days after drug administration
Global assessment of tolerability by the investigator on a 5-point rating scale
Time frame: 26 hours after drug administration
No study locations are listed for this record.
The record gives a start of Jan 2005 and a primary completion of Apr 2005. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tamsulosin